Literature DB >> 23610619

The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Raymond Lai1, Robert J Ingham.   

Abstract

Extensive research has been carried out in the past two decades to study the pathobiology of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), which is an oncogenic fusion protein found exclusively in a specific type of T-cell lymphoid malignancy, namely ALK-positive anaplastic large cell lymphoma. Results from these studies have provided highly useful insights into the mechanisms by which a constitutively tyrosine kinase, such as NPM-ALK, promotes tumorigenesis. Several previous publications have comprehensively summarized the advances in this field. In this review, we provide readers with a brief update on specific areas of NPM-ALK pathobiology. In the first part, the NPM-ALK/signal transducer and activator of transcription 3 (STAT3) signaling axis is discussed, with an emphasis on the existence of multiple biochemical defects that have been shown to amplify the oncogenic effects of this signaling axis. Specifically, findings regarding JAK3, SHP1 and the stimulatory effects of several cytokines including interleukin (IL)-9, IL-21 and IL-22 are summarized. New concepts stemming from recent observations regarding the functional interactions among the NPM-ALK/STAT3 axis, β catenin and glycogen synthase kinase 3β will be postulated. Lastly, new mechanisms by which the NPM-ALK/STAT3 axis promotes tumorigenesis, such as its modulations of Twist1, hypoxia-induced factor 1α, CD274, will be described. In the second part, we summarize recent data generated by mass spectrometry studies of NPM-ALK, and use MSH2 and heat shock proteins as examples to illustrate the use of mass spectrometry data in stimulating new research in this field. In the third part, the evolving field of microRNA in the context of NPM-ALK biology is discussed.

Entities:  

Keywords:  NPM-ALK; STAT3; anaplastic large cell lymphoma; oncogenic tyrosine kinase; signalling

Year:  2013        PMID: 23610619      PMCID: PMC3629756          DOI: 10.1177/2040620712471553

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN: 2040-6207


  98 in total

1.  Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.

Authors:  John Rush; Albrecht Moritz; Kimberly A Lee; Ailan Guo; Valerie L Goss; Erik J Spek; Hui Zhang; Xiang-Ming Zha; Roberto D Polakiewicz; Michael J Comb
Journal:  Nat Biotechnol       Date:  2004-12-12       Impact factor: 54.908

2.  NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

Authors:  Annamaria Galietta; Rosalind H Gunby; Sara Redaelli; Paola Stano; Cristiana Carniti; Angela Bachi; Philip W Tucker; Carmen J Tartari; Ching-Jung Huang; Emanuela Colombo; Karen Pulford; Miriam Puttini; Rocco G Piazza; Holger Ruchatz; Antonello Villa; Arianna Donella-Deana; Oriano Marin; Danilo Perrotti; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2007-05-30       Impact factor: 22.113

3.  Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS.

Authors:  Qian Zhang; Hongyi Wang; Kanchan Kantekure; Jennifer C Paterson; Xiaobin Liu; Andras Schaffer; Chrystal Paulos; Michael C Milone; Niels Odum; Suzanne Turner; Teresa Marafioti; Mariusz A Wasik
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

4.  Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.

Authors:  Fang Wu; Peng Wang; Jingdong Zhang; Leah C Young; Raymond Lai; Liang Li
Journal:  Mol Cell Proteomics       Date:  2010-04-14       Impact factor: 5.911

Review 5.  Biology of interleukin-22.

Authors:  Kerstin Wolk; Ellen Witte; Katrin Witte; Katarzyna Warszawska; Robert Sabat
Journal:  Semin Immunopathol       Date:  2010-02-02       Impact factor: 9.623

6.  Tyrosine phosphorylation and activation of JAK family tyrosine kinases by interleukin-9 in MO7E cells.

Authors:  T Yin; L Yang; Y C Yang
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

7.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

Review 8.  The anaplastic lymphoma kinase in the pathogenesis of cancer.

Authors:  Roberto Chiarle; Claudia Voena; Chiara Ambrogio; Roberto Piva; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

9.  Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.

Authors:  Karin Lange; Wolfgang Uckert; Thomas Blankenstein; Roger Nadrowitz; Cordula Bittner; Jean-Christophe Renauld; Jacques van Snick; Alfred C Feller; Hartmut Merz
Journal:  Oncogene       Date:  2003-01-30       Impact factor: 9.867

10.  Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.

Authors:  M Okabe; Y Uehara; T Miyagishima; T Itaya; M Tanaka; Y Kuni-Eda; M Kurosawa; T Miyazaki
Journal:  Blood       Date:  1992-09-01       Impact factor: 22.113

View more
  16 in total

1.  Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib.

Authors:  Prasanth Ganesan; Thanda Joshua; Shirley Sundersingh; Tenali Gnana Sagar
Journal:  Indian J Hematol Blood Transfus       Date:  2017-11-04       Impact factor: 0.900

2.  Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Authors:  Coralie Hoareau-Aveilla; Thibaud Valentin; Camille Daugrois; Cathy Quelen; Géraldine Mitou; Samuel Quentin; Jinsong Jia; Salvatore Spicuglia; Pierre Ferrier; Monica Ceccon; Sylvie Giuriato; Carlo Gambacorti-Passerini; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

3.  The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.

Authors:  Abdulraheem Alshareef; Hai-Feng Zhang; Yung-Hsing Huang; Chengsheng Wu; Jing Dong Zhang; Peng Wang; Ahmed El-Sehemy; Mohamed Fares; Raymond Lai
Journal:  Sci Rep       Date:  2016-09-19       Impact factor: 4.379

4.  High expression of β-catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma.

Authors:  Abdulraheem Alshareef; Nidhi Gupta; Hai-Feng Zhang; Chengsheng Wu; Moinul Haque; Raymond Lai
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

Review 5.  Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.

Authors:  Coralie Hoareau-Aveilla; Fabienne Meggetto
Journal:  Cancers (Basel)       Date:  2017-08-03       Impact factor: 6.639

6.  The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients.

Authors:  Abdulraheem Alshareef; Meredith S Irwin; Nidhi Gupta; Hai-Feng Zhang; Moinul Haque; Scott D Findlay; Bo Kyung Alex Seong; Justine Lai; Mohammed Rayis; Sadeq Al-Dandan; Raymond Lai
Journal:  Oncotarget       Date:  2018-01-12

Review 7.  Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.

Authors:  Abdulraheem Alshareef
Journal:  Cancers (Basel)       Date:  2017-10-28       Impact factor: 6.639

8.  STAT3 in Cancer-Friend or Foe?

Authors:  Hai-Feng Zhang; Raymond Lai
Journal:  Cancers (Basel)       Date:  2014-07-03       Impact factor: 6.639

9.  Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.

Authors:  Antoine Buetti-Dinh; Thomas O'Hare; Ran Friedman
Journal:  PLoS One       Date:  2016-09-26       Impact factor: 3.240

Review 10.  The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL).

Authors:  Ivonne A Montes-Mojarro; Julia Steinhilber; Irina Bonzheim; Leticia Quintanilla-Martinez; Falko Fend
Journal:  Cancers (Basel)       Date:  2018-04-04       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.